Premium
Effects of captopril on factors affecting gastric mucosal integrity in aspirin‐induced gastric lesions in Sprague‐Dawley rats
Author(s) -
Ismai Nafeeza Mohd,
Aziz Ibrahim Abdel,
Jaarin Kamsiah
Publication year - 2012
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.26.1_supplement.848.8
Subject(s) - captopril , ranitidine , aspirin , pharmacology , medicine , glutathione , chemistry , enzyme , biochemistry , blood pressure
Captopril, an angiotensin converting enzyme inhibitor, used as an antihypertensive agent has been shown to have antioxidant properties which prompted the present study. This study investigated the effects of captopril on factors affecting gastric mucosal integrity in rats that had aspirin‐induced gastric lesions. Eighteen male Sprague‐Dawley (200–250g) rats given aspirin (40 mg/100g bw) were divided into a control group, captopril (1 mg/100g bw daily) and ranitidine (2.5 mg/100g bw bidaily) groups. Oral ranitidine and captopril were given for 28 days. Compared with the control group, captopril reduced gastric acidity (P<0.05), increased gastric GSH (P<0.05) and prostaglandin E 2 (P<0.05). Ranitidine healed the lesions significantly (P<0.05) compared to the control group. There was, however no difference between ranitidine and captopril on the severity of lesions, gastric acidity, MDA and GSH. Captopril increased PGE 2 compared to ranitidine (P<0.05). In conclusion, we found that captopril produced desirable effects on gastric acidity, PGE 2 and GSH. Its capability to enhanced gastroprotective protective parameters and reduce the aggressive acid‐factor optimises the balance between protective and aggressive factors. In view of this linkage, we strongly suggest captopril as a potential novel antiulcer agent. Research was funded by the Faculty of Medicine, Universiti Kebangsaan Malaysia.